AbbVie (ABBV) Non Operating Interest Expenses (2012 - 2018)

AbbVie (ABBV) has reported Non Operating Interest Expenses for 6 consecutive years, with $500.0 million the latest figure, recorded in Q2 2018.

• On a quarterly basis, Non Operating Interest Expenses changed N/A year-over-year to $500.0 million in Q2 2018; TTM through Jun 2019 was $500.0 million, a 0.0% change from a year earlier, with the FY2018 full-year figure at $500.0 million, changed N/A from the prior year.
• Non Operating Interest Expenses was $500.0 million for Q2 2018 at AbbVie, up from $245.0 million in the prior quarter.
• Over five years, Non Operating Interest Expenses peaked at $500.0 million in Q2 2018 and troughed at -$511.0 million in Q4 2015.
• A 4-year average of $164.8 million and a median of $207.0 million in 2015 frame the typical range for Non Operating Interest Expenses.
• Across the five-year window, Non Operating Interest Expenses surged 521.62% in 2014 and sank 211.09% in 2015, its largest moves.
• Over 4 years, Non Operating Interest Expenses stood at $460.0 million in 2014, then slumped by 211.09% to -$511.0 million in 2015, then soared by 147.95% to $245.0 million in 2016, then jumped by 104.08% to $500.0 million in 2018.
• The last three Non Operating Interest Expenses figures came in at $500.0 million (Q2 2018), $245.0 million (Q2 2016), and $215.0 million (Q1 2016), per Business Quant data.